Study identifier:D2287R00105
ClinicalTrials.gov identifier:NCT03425760
EudraCT identifier:N/A
CTIS identifier:N/A
A cross-sectional study of COPD and symptom variability in MEA countries
Chronic Obstructive Pulmonary Disease
N/A
No
-
All
3254
Observational
N/A
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jun 2018 by AstraZeneca
AstraZeneca
-
This non-interventional study aims at assessing stable GOLD C and D COPD patient’s perception of daily and weekly symptoms variability and their impact on daily activities. It will also explore the current practice in management of stable GOLD C and D COPD patients.
(a)Primary objective: To assess perception of daily and weekly variability of symptoms in stable GOLD C and D COPD patients and their impact on daily life activities (b) Secondary objectives: - To describe the current treatment practice for the management of GOLD C and D COPD in MEA countries and their adherence to the GOLD 2015 guidelines - To compare patients’ perception of symptoms variability and their impact on activities between Gold categories C and D - To identify demographic, behavioral and clinical factors associated with symptoms variability.
No locations available
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.